Literature DB >> 10492863

Malignant catatonia-induced respiratory failure with response to ECT.

B K Boyarsky1, M Fuller, T Early.   

Abstract

A 47-year-old acutely psychotic schizophrenic man was diagnosed with malignant catatonia. Because of a history of neuroleptic malignant syndrome (NMS), traditional neuroleptics were avoided, and the patient had been treated with reserpine for a period of 10 years. Symptomatically, severe agitation alternated with severe retardation. The syndrome progressed, despite early termination of any neuroleptic medications, to marked catatonic rigidity and dehydration. Worsening was associated with transfer to a medical intensive care unit, intubation, and subsequently a tracheostomy. Dantrolene and bromocriptine were unhelpful. Lorazepam produced muscular relaxation and resulting decreases in creatine phosphokinase levels but elicited no other improvement. Eleven bilateral electroconvulsive treatments, however, resolved the respiratory impairment and catatonia and improved the psychosis. This report highlights the efficacy of ECT in lethal catatonia despite respiratory impairment and tracheostomy.

Entities:  

Mesh:

Year:  1999        PMID: 10492863

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  3 in total

1.  Response to benzodiazepines and the clinical course in malignant catatonia associated with schizophrenia: A case report.

Authors:  Kazutaka Ohi; Aki Kuwata; Takamitsu Shimada; Toshiki Yasuyama; Yusuke Nitta; Takashi Uehara; Yasuhiro Kawasaki
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

2.  Malignant Catatonia Warrants Early Psychiatric-Critical Care Collaborative Management: Two Cases and Literature Review.

Authors:  Julia Park; Josh Tan; Sylvia Krzeminski; Maryam Hazeghazam; Meghana Bandlamuri; Richard W Carlson
Journal:  Case Rep Crit Care       Date:  2017-01-30

3.  Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors.

Authors:  Stanley N Caroff
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-05-31       Impact factor: 2.582

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.